TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

This study is testing TY-9591 — a new targeted therapy that blocks a protein called EGFR — in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain. The drug is designed to cross the blood-brain barrier, addressing a challenge that many lung cancer treatments face. **You may be eligible if...** - You are between 18 and 80 years old with NSCLC confirmed by biopsy or cytology - Your tumor has an EGFR mutation (exon 19 deletion, L858R, or similar) - You have stable brain metastases that do not need immediate treatment - You have not yet received systemic (whole-body) treatment for advanced NSCLC - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - You have previously received any EGFR inhibitor or systemic cancer treatment - You have had whole-brain radiation therapy - Your brain metastases are unstable or require urgent treatment - You have serious heart problems, interstitial lung disease, or active viral infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.